Therapeutic strategies for Alzheimer’s disease in clinical trials

[1]  J. Fuentealba,et al.  ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of β-amyloid peptide in hippocampal neurons , 2016, Neuropharmacology.

[2]  P. Moreau,et al.  Frontline therapy of multiple myeloma. , 2015, Blood.

[3]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[4]  C. Holmes,et al.  Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease , 2015, The Journal of pathology.

[5]  M. Youdim,et al.  New Approaches to Treating Alzheimer’s Disease , 2015, Perspectives in medicinal chemistry.

[6]  F. Grüninger.  Invited review: Drug development for tauopathies , 2015, Neuropathology and applied neurobiology.

[7]  Dawid Panek,et al.  Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease , 2014, Current medicinal chemistry.

[8]  B. Dubois,et al.  A phase II trial of tideglusib in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[9]  R. Vassar.  BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[10]  J. Götz,et al.  Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.

[11]  M. Sabbagh,et al.  Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat. , 2014, American journal of neurodegenerative disease.

[12]  L. Schneider.  Idalopirdine for Alzheimer's disease: written in the stars , 2014, The Lancet Neurology.

[13]  Kristian Windfeld,et al.  Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial , 2014, The Lancet Neurology.

[14]  N. Greig,et al.  Lessons from a BACE1 inhibitor trial: Off-site but not off base , 2014, Alzheimer's & Dementia.

[15]  R. Segurado,et al.  NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease , 2014, BMJ Open.

[16]  H. Qing,et al.  Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond β-Amyloid: Insights from Clinical Trials , 2014, BioMed research international.

[17]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[18]  I. Mook‐Jung,et al.  Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease , 2014, Journal of Korean medical science.

[19]  S. Dutta,et al.  The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers. , 2014, British journal of clinical pharmacology.

[20]  B. Winblad,et al.  The battle of Alzheimer’s Disease – the beginning of the future Unleashing the potential of academic discoveries , 2014, Front. Pharmacol..

[21]  N. Relkin.  Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease , 2014, Journal of Clinical Immunology.

[22]  A. Fleisher,et al.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. , 2014, The Journal of clinical psychiatry.

[23]  Thomas Wisniewski,et al.  Immunotherapy for Alzheimer's disease. , 2014, Biochemical pharmacology.

[24]  George Perry,et al.  The complexities of the pathology-pathogenesis relationship in Alzheimer disease. , 2014, Biochemical pharmacology.

[25]  C. Harrington,et al.  Tau-aggregation inhibitor therapy for Alzheimer's disease. , 2014, Biochemical pharmacology.

[26]  Young Chul Youn,et al.  The genetics of Alzheimer’s disease , 2014, Clinical interventions in aging.

[27]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[28]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[29]  E. Siemers,et al.  Amyloid-ß-directed immunotherapy for Alzheimer's disease , 2014, Journal of internal medicine.

[30]  G. Logroscino,et al.  Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? , 2014, Current opinion in psychiatry.

[31]  N. Andreasen,et al.  Pathways to Alzheimer's disease , 2014, Journal of internal medicine.

[32]  P. Mecocci,et al.  Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.

[33]  G. Logroscino,et al.  Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward , 2014, Expert review of clinical immunology.

[34]  R. Raffa,et al.  Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches , 2014, Journal of clinical pharmacy and therapeutics.

[35]  A. Roses,et al.  New applications of disease genetics and pharmacogenetics to drug development. , 2014, Current opinion in pharmacology.

[36]  Abbas Ali Mahdi,et al.  Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.

[37]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[38]  M. Sabbagh,et al.  Effect of TTP488 in patients with mild to moderate Alzheimer’s disease , 2014, BMC Neurology.

[39]  G. Rutigliano,et al.  The 5-HT6 receptor antagonism approach in Alzheimer's disease , 2014, Drugs of the Future.

[40]  P. Maruff,et al.  A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. , 2014, Current Alzheimer Research.

[41]  A. Othman,et al.  A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.

[42]  Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study , 2014, Alzheimer's Research & Therapy.

[43]  D. Galimberti,et al.  Disease-modifying drugs in Alzheimer’s disease , 2013, Drug design, development and therapy.

[44]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[45]  M N Rossor,et al.  Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. , 2013, Revue neurologique.

[46]  E. Marcello,et al.  ADAM10 in Synaptic Physiology and Pathology , 2013, Neurodegenerative Diseases.

[47]  F. van Leuven,et al.  Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.

[48]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[49]  B. Dubois,et al.  A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (ARGO trial) , 2013, Alzheimer's & Dementia.

[50]  D. Wilkinson,et al.  A clinical phase II study of Lu AE58054 added to stable donepezil treatment in patients with moderate Alzheimer's disease , 2013, Alzheimer's & Dementia.

[51]  E. Liu,et al.  Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial , 2013, Alzheimer's & Dementia.

[52]  A. Roses,et al.  Using Genetics to Enable Studies on the Prevention of Alzheimer's Disease , 2013, Clinical pharmacology and therapeutics.

[53]  M. Pai,et al.  Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor. , 2013, Journal of the American Academy of Dermatology.

[54]  John Bond,et al.  The worldwide economic impact of dementia 2010 , 2013, Alzheimer's & Dementia.

[55]  Xuefeng Yu,et al.  Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. , 2012, Journal of Alzheimer's disease : JAD.

[56]  David J. Fleet,et al.  Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.

[57]  Suzanne Craft,et al.  Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[58]  A. Gjedde,et al.  Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial. , 2012, Danish medical journal.

[59]  Min Zhang,et al.  Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist , 2012, Journal of Pharmacology and Experimental Therapeutics.

[60]  M. Pangalos,et al.  Treatment strategies targeting amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[61]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[62]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[63]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[64]  U. Schepers,et al.  Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons , 2012, The EMBO journal.

[65]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[66]  Bikram Singh,et al.  Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity. , 2012, Current topics in medicinal chemistry.

[67]  N. Greig,et al.  Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease , 2012, Journal of Neuroinflammation.

[68]  A. Roses,et al.  Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations , 2012, PloS one.

[69]  D. Bertrand,et al.  EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.

[70]  R. Mahley,et al.  Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* , 2011, The Journal of Biological Chemistry.

[71]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[72]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[73]  D. Kovacs,et al.  The many substrates of presenilin/γ-secretase. , 2011, Journal of Alzheimer's disease : JAD.

[74]  S. Morisset,et al.  [The histaminergic system: a target for innovative treatments of cognitive deficits]. , 2010, Therapie.

[75]  M. Gold,et al.  Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. , 2010, Current Alzheimer research.

[76]  M. Solas,et al.  Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. , 2010, The international journal of neuropsychopharmacology.

[77]  J. Arrang,et al.  [The histaminergic system: a target for innovative treatments of cognitive deficits]. , 2010, Therapie.

[78]  Talib F. Abbas,et al.  Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease , 2009, Behavioural Brain Research.

[79]  T. Gómez-Isla,et al.  A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo , 2009, Neurobiology of Disease.

[80]  M. Novák.  Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy , 2009, Alzheimer's & Dementia.

[81]  F. Gil-Bea,et al.  Effects of 5‐HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat , 2008, British journal of pharmacology.

[82]  K. Browman,et al.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders , 2008, British journal of pharmacology.

[83]  P. Mehta,et al.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[84]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[85]  B. Imbimbo.  Therapeutic potential of gamma-secretase inhibitors and modulators. , 2008, Current topics in medicinal chemistry.

[86]  M. Reger,et al.  Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.

[87]  A. Astell,et al.  Molecular connexions between dementia and diabetes , 2007, Neuroscience & Biobehavioral Reviews.

[88]  D. Lockwood,et al.  The role of thalidomide in the management of erythema nodosum leprosum. , 2007, Leprosy review.

[89]  T. Golde.  The Pathogenesis of Alzheimer's Disease and the Role of Aβ42 , 2007, CNS Spectrums.

[90]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[91]       .  Global prevalence of dementia: a Delphi consensus study , 2006 .

[92]  D. M. Robinson,et al.  Memantine: a review of its use in Alzheimer's disease. , 2006, Drugs.

[93]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[94]  N. Greig,et al.  Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. , 2004, Acta neurobiologiae experimentalis.

[95]  K. Blennow,et al.  Intrathecal inflammation precedes development of Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[96]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[97]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[98]  D. Cleveland,et al.  Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. , 2001, Current opinion in cell biology.

[99]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[100]  E Lai,et al.  A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. , 1998, Genomics.

[101]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[102]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[103]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[104]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.